Nanoform, a nanoparticle medicine enabling company, has signed a GMP manufacturing program (clinical development) to enhance TargTex’s Glioblastoma multiforme drug candidate. The program starts with aPoP (Proof of Process) phase.   This follows a successful PoC (Proof of Concept) study where the hydrogel formulation developed by Nanoform (CESS technology-based nanoparticles) enabled a fivefold increase in drug load compared to nanomilling, the less effective alternative.   TargTex, a Europea...